These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12523468)

  • 1. Recurring chemotherapy-associated alopecia areata: case report and literature review.
    Motl SE; Fausel C
    Pharmacotherapy; 2003 Jan; 23(1):104-8. PubMed ID: 12523468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
    Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
    J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alopecia areata following adalimumab.
    Kirshen C; Kanigsberg N
    J Cutan Med Surg; 2009; 13(1):48-50. PubMed ID: 19298772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
    Oskay-Ozcelik G; Chekerov R; Sommer H; Keil E; Einenkel J; Pfisterer J; Lorenz-Schlüter C; Lichtenegger W; Camara O; Sehouli J
    Gynecol Oncol; 2010 Mar; 116(3):317-22. PubMed ID: 19959213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and carboplatin as outpatient therapy for stage III and IV epithelial ovarian cancer.
    Balbi GC; Menditto A; Calabria G; Musone R; Di Prisco L; Cassese E; Balbi C; Cardone A
    Panminerva Med; 2001 Dec; 43(4):263-5. PubMed ID: 11677421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case report of complete response by TS-1 and paclitaxel combination chemotherapy for advanced gastric cancer].
    Kodama T; Ishida H; Okino T; Okamoto R; Takahashi H; Hayashi N; Mori K; Noguchi M
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1159-62. PubMed ID: 16912540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer.
    Ozguroglu M; Sari O; Turna H
    Int J Gynecol Cancer; 2006; 16 Suppl 1():394-6. PubMed ID: 16515631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
    Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
    Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.
    Kudlowitz D; Velastegui A; Musa F; Muggia F
    Cancer Chemother Pharmacol; 2018 May; 81(5):847-851. PubMed ID: 29516152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
    Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
    Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rectal perforation following paclitaxel and carboplatin chemotherapy for advanced ovarian cancer: a case report and review of the literature.
    Jayakody S; Wright DB; Chiong C; Liu M; Bouffler C; El-Khoury T
    J Med Case Rep; 2018 Aug; 12(1):221. PubMed ID: 30111379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?
    Higgins RV; Naumann RW; Gardner J; Hall JB
    Gynecol Oncol; 1999 Dec; 75(3):464-7. PubMed ID: 10600308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
    Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
    Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.
    Gadducci A; Gargini A; Palla E; Fanucchi A; Genazzani AR
    Anticancer Res; 2005; 25(3c):2509-13. PubMed ID: 16080485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.